Clinical Trials Logo

Clinical Trial Summary

Periodontitis is an inflammatory pathology that destroys periodontitis and causes tooth loosening. Its high incidence, combined with very high oral and systemic morbidity, places this pathology at the heart of global public health priorities. The current therapeutic management of periodontitis is not satisfactory because it often leads to a stabilization of the disease, marked by frequent recurrences, especially severe forms. Improving the treatment of patients with periodontitis is therefore an essential priority. If gingival bacterial dysbiosis is a major contributing factor, this model has clinical-biological limitations that suggest that other etiological factors are involved, and worsen the pathology. In particular, the literature provides clear evidence that periodontal lesions are mostly infected with Herpes EBV, CMV and HSV-1 viruses and that periodontal infection with these viruses is very directly correlated with disease progression (severity). In addition, our work provides new cellular and molecular data that demonstrate mechanisms of active EBV infection of cells and periodontal structures, and highlight inflammatory and necrotic effects associated with this infection. Given these observations and the high pathogenicity of herpes viruses, all known to be powerful inflammatory, lytic and immunomodulatory agents, it seems difficult not to evoke a direct etiopathogenic role of these viruses capable of acting synergistically with periodontopathogenic bacteria. In this context, the use of an antiviral appears as a very attractive therapeutic proposal to effectively treat periodontitis in combination with conventional treatments. This original and innovative proposal can also be easily and quickly validated in a randomized therapeutic trial through the availability of antiviral molecules that are non-toxic and very specific to human herpes viruses that are derivatives of aciclovir.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05902208
Study type Interventional
Source Centre Hospitalier Universitaire de Nice
Contact Séverine VINCENT-BUGNAS
Phone 04 92 03 32 70
Email vincent-bugnas.s@chu-nice.fr
Status Recruiting
Phase Phase 3
Start date February 5, 2024
Completion date May 2026

See also
  Status Clinical Trial Phase
Completed NCT06041178 - Flurbiprofen Versus Aloe Vera Gel in the Treatment of Chronic Periodontitis in Smoking Patients. Phase 4
Not yet recruiting NCT06016023 - Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker
Not yet recruiting NCT04444063 - Clinical and Radiograhic Evaluation of NIPSA With and Without Allograft Plus Platelet Rich Fibrin in the Treatment of Intraosseous Defects in Stage III Periodontitis Patients N/A
Recruiting NCT05548933 - Effects of Non-surgical Periodontal Therapy on Severe Periodontitis and Hyperlipidemia
Withdrawn NCT04978324 - Scaling and Root Planning With Localized Delivery of Autogenous Growth Factors- Platelet Rich Fibrin (PRF) Phase 3
Completed NCT05768243 - Hyaluronic Acid Versus Red Injectable Platelet Rich Fibrin in Treatment of Periodontitis Phase 4
Recruiting NCT05698823 - Regular Home-use of Dual-light Photodynamic Therapy in the Management of Chronic Stage III-IV Periodontitis N/A
Completed NCT04027686 - Clinical Evaluation of Laser Therapy Used as an Adjunct to Non-Surgical Treatment of Gum Disease N/A